Myomics, Phantomics' Cardiac MRI AI Solution, Selected for the Seoul Awards 2024

Phantomics (CEOs Byoung Wook Choi and Pan Ki Kim), a medical imaging AI innovator, announced on January 16 that its cardiac MRI innovation solution Myomics has been selected for the Seoul Awards 2024.
The Seoul Awards is a product-certification support program of the Seoul Business Agency (SBA) that recognizes outstanding products from Seoul-based SMEs representing the Seoul lifestyle. Products are selected with an emphasis on global competitiveness in order to support overseas market development and export expansion. Through the selection, Phantomics will receive support from the SBA Global Marketing Center, including exhibition in the Seoul Awards Lounge and promotional assistance.
According to Phantomics, Myomics automatically analyzes and quantifies cardiac MRI images using artificial intelligence to safely and accurately diagnose suspected myocardial diseases such as heart failure, myocarditis and amyloidosis, cutting image-analysis time from about 30 minutes to under two minutes. It also enables standardized analysis that reduces variation between hospitals while delivering accuracy comparable to biopsy. The company said the selection recognizes the innovation and excellence of combining AI with medical imaging to deliver fast and accurate diagnostic results.
Myomics has been recognized for helping clinicians treat patients quickly and is currently used at more than 20 tertiary university hospitals in Korea as well as in Japan, Taiwan, Singapore and other countries. Last year it became the first in Korea's medical imaging AI industry to win the CES 2024 Innovation Award and the FIX 2024 Innovation Awards Grand Prize.
Phantomics is a faculty start-up from Yonsei University Severance Hospital founded to overcome cardiovascular disease. It develops medical solutions that combine AI with non-invasive diagnostics to deliver fast, accurate results. Its flagship solutions are Myomics, a cardiac MRI-based AI solution, and Angiomics, a cardiac CT-based solution. The company has obtained medical device approvals for more than five products from the U.S. FDA and Korea's MFDS.